IORT per cancro al seno stadio
innovationMADE BY ZEISS
Offrire alternative adeguate ai rischi per trattamenti conservativi del seno. Soluzioni IORT di ZEISS
innovationMADE BY ZEISS

Cancro al seno

Scoprite di più

Sales Request

Any questions about buying our products?

Contact us now

Price Request

Our Sales Team will contact you shortly.

Request a Quote

Schedule your Consultation

Our experts will contact you shortly.

Schedule an Appointment

Customer Care

Need assistance with your product?

Contact us now

Argomenti correlati

  • 1 Vaidya, J. S., Wenz, F., Bulsara, M., Tobias, J. S., Joseph, D. J., Keshtgar, M., … Baum, M. (2014). Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. The Lancet, 383(9917), 603–613.
  • 2 Vaidya, J. S., Joseph, D. J., Tobias, J. S., Bulsara, M., Wenz, F., Saunders, C., … Baum, M. (2010). Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. The Lancet, 376(9735), 91–102.
  • 3 Vaidya, J. (2013). “1-stop” radiotherapy could offer an alternative to lengthy and inconvenient post-surgery procedures for breast cancer.